Advancements in Biomedical Research: Insights from SLAS Discovery, Volume 29, Issue 1

For Immediate Release

Exploring Innovations in Type-1 Diabetes Therapies, Drug Discovery
Hepatic Stability, and Anti-Influenza Drug Screening

Oak Brook, IL (March 15, 2024) – Volume 29, Issue 1 of SLAS Discovery features two review articles, five original research articles pertaining to Type-1 diabetes therapies, hepatic stability in drug discovery and anti-influenza drug screening and one short communication.


Original Research

Short Communication

  • Virtual Plates: Getting the Best Out of High Content Screens
    This communication highlights the need for automated hit analysis and detection methods in high content screening (HCS). The study builds upon a statistical framework and introduces a novel concept called Virtual Plates, providing an automated approach to HCS hit detection. This facilitates data analysis and enhances accessibility to hit data despite technical issues encountered during screening campaigns.

Access to this issue of SLAS Discovery is available at


SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that:

  • Enables and improves target validation
  • Evaluates current drug discovery technologies
  • Provides novel research tools
  • Incorporates research approaches that enhance depth of knowledge and drug discovery success

SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Discovery: Advancing the Science of Drug Discovery, 2022 Impact Factor 3.1. Editor-in-Chief Robert M. Campbell, Ph.D., Redona Therapeutics, Watertown, MA (USA)


Contact Information

Jill Hronek

Director of Marketing Communications

Telephone: +1.630.256.7527, ext. 103